IRIS
TACCONELLI, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 3.275
EU - Europa 3.247
AS - Asia 2.025
SA - Sud America 187
AF - Africa 29
Continente sconosciuto - Info sul continente non disponibili 6
OC - Oceania 4
Totale 8.773
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 3.249
SG - Singapore 746
CN - Cina 724
UA - Ucraina 528
IE - Irlanda 507
IT - Italia 488
GB - Regno Unito 387
SE - Svezia 353
TR - Turchia 349
FR - Francia 332
DE - Germania 224
BR - Brasile 180
FI - Finlandia 134
PL - Polonia 106
RU - Federazione Russa 96
IN - India 88
HK - Hong Kong 33
CZ - Repubblica Ceca 27
BE - Belgio 23
VN - Vietnam 17
AT - Austria 14
BD - Bangladesh 12
MX - Messico 12
CA - Canada 11
ZA - Sudafrica 11
JP - Giappone 10
NL - Olanda 10
AE - Emirati Arabi Uniti 9
IR - Iran 7
EU - Europa 5
LY - Libia 5
BY - Bielorussia 4
EG - Egitto 4
IQ - Iraq 4
MA - Marocco 4
AU - Australia 3
ES - Italia 3
GR - Grecia 3
IL - Israele 3
PK - Pakistan 3
SA - Arabia Saudita 3
AR - Argentina 2
AZ - Azerbaigian 2
EC - Ecuador 2
LT - Lituania 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
RO - Romania 2
TH - Thailandia 2
UZ - Uzbekistan 2
A2 - ???statistics.table.value.countryCode.A2??? 1
AL - Albania 1
BN - Brunei Darussalam 1
CG - Congo 1
CH - Svizzera 1
CO - Colombia 1
DZ - Algeria 1
EE - Estonia 1
GA - Gabon 1
GT - Guatemala 1
HN - Honduras 1
ID - Indonesia 1
JM - Giamaica 1
JO - Giordania 1
KE - Kenya 1
KZ - Kazakistan 1
NO - Norvegia 1
NP - Nepal 1
NZ - Nuova Zelanda 1
TN - Tunisia 1
UY - Uruguay 1
VE - Venezuela 1
Totale 8.773
Salva come PNG Salva come JPEG
Città #
Chandler 662
Jacksonville 583
Singapore 550
Dublin 498
Southend 312
Princeton 220
Dearborn 182
Izmir 170
Nanjing 155
Ashburn 125
Beijing 111
Wilmington 101
Kraków 98
Cambridge 96
Tongling 84
Chieti 83
Altamura 79
The Dalles 71
Ann Arbor 67
Nanchang 64
Boardman 53
Santa Clara 53
Munich 50
Shenyang 42
Woodbridge 38
Los Angeles 34
Hong Kong 33
Hebei 29
Changsha 28
Grevenbroich 27
Pescara 27
Helsinki 25
New York 24
Jiaxing 23
Brno 22
Tianjin 22
Kocaeli 21
Washington 21
Brussels 20
Kunming 20
Camerino 19
Orange 17
Seattle 17
Shanghai 17
São Paulo 17
Hangzhou 16
Spoltore 16
Norwalk 15
Nuremberg 13
Chicago 12
Düsseldorf 12
Rome 12
Hefei 11
Jinan 11
Leawood 11
Lanzhou 10
Dong Ket 9
Guangzhou 9
Lappeenranta 9
Augusta 8
Brooklyn 8
Houston 8
Montesilvano 8
Romola 8
Turku 8
Vienna 8
Cape Town 7
Menlo Park 7
Warsaw 7
Brasília 6
Dubai 6
Fuzhou 6
L’Aquila 6
Mumbai 6
Ningbo 6
San Mateo 6
Silvi 6
Simi Valley 6
Amsterdam 5
Auburn Hills 5
Belo Horizonte 5
Frankfurt am Main 5
Mexico City 5
Moscow 5
Olomouc 5
Padova 5
Perm 5
Rio de Janeiro 5
Taizhou 5
Tavagnacco 5
Ankara 4
Changchun 4
Charlotte 4
Hanoi 4
Mogilev 4
San Francisco 4
Tappahannock 4
Zhengzhou 4
Ardabil 3
Atlanta 3
Totale 5.405
Salva come PNG Salva come JPEG
Nome #
“DERIVATI ISOSSAZOLICI E LORO IMPIEGO COME INIBITORI DELLA CICLOOSSIGENASI” 199
Low-dose aspirin acetylates cyclooxygenase-1 in human colorectal mucosa: implications for the chemoprevention of colorectal cancer. 134
Response to "Pharmacodynamic Interaction Between Aspirin and Ibuprofen: A Plausible Mechanism of Aspirin Resistance" 121
Reduced variability to aspirin antiplatelet effect by the coadministration of statins in high-risk patients for cardiovascular disease. 120
ROLE OF DOSE POTENCY IN THE PREDICTION OF RISK OF MYOCARDIAL INFARCTION ASSOCIATED WITH NONSTEROIDAL ANTI-INFLAMMATORY DRUGS IN THE GENERAL POPULATION. 119
Reappraisal of the clinical pharmacology of low-dose aspirin by comparing novel direct and traditional indirect biomarkers of drug action 116
Dysregulated post-transcriptional control of COX-2 gene expression in gestational diabetic endothelial cells 114
The biochemical selectivity of novel COX-2 inhibitors in whole blood assays of COX-isozyme activity. 113
Nonsteroidal anti-inflammatory drugs and cardiovascular safety - translating pharmacological data into clinical readouts. 111
Effects of AF3442 [N-(9-ethyl-9H-carbazol-3-yl)-2-(trifluoromethyl)benzamide], a novel inhibitor of human microsomal prostaglandin E synthase-1, on prostanoid biosynthesis in human monocytes in vitro. 104
Antithrombotic Agents and Cancer 103
Platelet-specific deletion of cyclooxygenase-1 ameliorates dextran sulfate sodium-induced colitis in mice. 102
Oxidative stress and platelet activation in essential hyperytension 99
THE SELECTIVITY OF NOVEL COX-2 INHIBITORS IN HUMAN WHOLE BLOOD ASSAYS OF COX-ISOZYME ACTIVITY. 99
Grand challenges in pharmacotherapy of inflammation for the first decades of the 21st century. 99
Measurement of 8-iso-prostaglandin F2alpha in biological fluids as a measure of lipid peroxidation 99
New insights into COX-2 biology and inhibition. 98
miR-574-5p as RNA decoy for CUGBP1 stimulates human lung tumor growth by mPGES-1 induction. 98
Platelet activation in patients with colorectal cancer. 97
Low-dose naproxen interferes with the antiplatelet effects of aspirin in healthy subjects: recommendations to minimize the functional consequences 97
Mechanisms of the antitumoural effects of aspirin in the gastrointestinal tract. 97
PROSTAGLANDIN E2-MEDIATED ACTIVATION OF PHOSPHATIDYLINOSITOL 3-OH KINASE DIFFERENTIALLY AFFECTS IL-10 AND IL-1β PRODUCTION IN BLOOD CELLS. 94
ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS 94
Role of dose potency in the prediction of risk of myocardial infarction associated with nonsteroidal anti-inflammatory drugs in the general population. 94
The future of traditional nonsteroidal antiinflammatory drugs and cyclooxygenase-2 inhibitors in the treatment of inflammation and pain. 91
Effects of estrogen on endothelial prostanoid production and cyclooxygenase-2 and heme oxygenase-1 expression. 91
CYCLOOXYGENASE-2-DERIVED PROSTACYCLIN RESTRAIN PLATELET THROMBOXANE BIOSYNTHESIS IN TOLL-LIKE RECEPTOR 4 POLYMORPHISM 90
Modulation of prostaglandin h synthase-2 (pghs-2) expression in human monocytes by glucocorticoids. 89
Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. 89
Mechanistic and pharmacological issues of aspirin as an anticancer agent 89
Heterogeneity in the suppression of platelet cyclooxygenase-1 activity by aspirin in coronary heart disease 89
OXIDATIVE STRESS AND PLATELET ACTIVATION IN HUMAN ESSENTIAL HYPERTENSION. 88
Reduced thromboxane biosynthesis in carriers of toll-like receptor 4 polymorphisms in vivo. 88
Clinical pharmacology of selective COX-2 inhibitors. 87
Synthesis, pharmacological characterization, and docking analysis of a novel family of diarylisoxazoles as highly selective cyclooxygenase-1 (COX-1) inhibitors. 87
Pharmacodynamic of cyclooxygenase inhibitors in humans. 86
Celecoxib, ibuprofen, and the antiplatelet effect of aspirin in patients with osteoarthritis and ischemic heart disease 85
Effects of celecoxib on prostanoid biosynthesis and circulating angiogenesis proteins in familial adenomatous polyposis. 85
Pharmacological Characterization of the Microsomal Prostaglandin E2 Synthase-1 Inhibitor AF3485 In Vitro and In Vivo 84
Effects of Acetaminophen on Constitutive and Inducible Prostanoid Biosynthesis in Human Blood Cells in vitro 82
EFFECTS OF CELECOXIB ON SYSTEMIC MARKERS OF PROSTANOID GENERATION AND INFLAMMATION AND ANGIOGENESIS IN PATIENTS WITH FAMILIAL ADENOMATOUS POLYPOSIS: A BIOMARKER CLINICAL STUDY. 82
LOW-DOSE NAPROXEN INTERFERES WITH THE ANTIPLATELET EFFECT OF LOW-DOSE ASPIRIN IN HEALTHY SUBJECTS. 82
Clinical pharmacology of novel selective COX-2 inhibitors. 82
The human pharmacology of monocyte cyclooxygenase 2 inhibition by cortisol and synthetic glucocorticoids. 82
Altered release of cytochrome p450 metabolites of arachidonic acid in renovascular disease. 82
Clinical pharmacology of cyclooxygenase inhibition and pharmacodynamic interaction with aspirin by floctafenine in Thai healthy subjects. 82
De novo synthesis of cyclooxygenase-1 counteracts the suppression of platelet thromboxane biosynthesis by aspirin. 81
INIBITORI SELETTIVI DI COX-2: LE NUOVE MOLECOLE 81
Cardiovascular effects of valdecoxib: transducing human pharmacology results into clinical read-outs. 81
Gut microbiota, host gene expression, and aging. 81
“ISOXAZOLE DERIVATIVES AND THEIR USE AS CYCLOOXYGENASE INHIBITORS" 80
CLINICAL PHARMACOLOGY OF CYCLOOXYGENASE INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 80
Incomplete suppression of platelet COX-1 activity associated with aspirin-resistant thromboxane biosynthesis in acute coronary syndromes 80
Variability in the Response to Non-Steroidal Anti-Inflammatory Drugs: Mechanisms and Perspectives. 80
Increased oxidative stress and platelet activation in patients with hypertension and renovascular disease. 78
Pharmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 78
Risk management profile of etoricoxib: An example of personalized medicine 78
Determinants of platelet activation in human essential hypertension. 78
“DIARILISOSSAZOLI FUNZIONALIZZATI INIBITORI DELLA CICLOSSIGENASI” 77
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 77
NSAIDs and cardiovascular disease. 77
Dose- Dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects. 76
NSAIDs and cardiovascular disease: transducing human pharmacology results into clinical read-outs in the general population. 76
Celecoxib, ibuprofen and the antiplatelet effect of aspirin in patients with osteoarthritis and chronic stable angina 76
P2Y12 Receptors in Tumorigenesis and Metastasis 76
Characterization of cyclooxygenase-2 acetylation and prostanoid inhibition by aspirin in cellular systems 74
Clinical pharmacology of etoricoxib. 73
DIFFERENTIAL ASSOCIATION BETWEEN HUMAN PROSTACYCLIN RECEPTOR POLYMORPHISMS AND THE DEVELOPMENT OF VENOUS THROMBOSIS AND INTIMAL HYPERPLASIA: A CLINICAL BIOMARKER STUDY. 71
Enhanced thromboxane biosynthesis in patients with colorectal and lung cancer 71
Human pharmacology of naproxen sodium. 71
CLINICAL PHARMACOLOGY OF PLATELET COX INHIBITION BY NAPROXEN AND LOW-DOSE ASPIRIN. 70
Dose-dependent inhibition of platelet cyclooxygenase-1 and monocyte cyclooxygenase-2 by meloxicam in healthy subjects 70
Novel synthesis of 3,4-diarylisoxazole analogues of valdecoxib: reversal cyclooxygenase-2 selectivity by sulfonamide group removal. 70
INHIBITION OF INDUCILE CYCLOOXYGENASE ACTIVITY BY GLUCOCORTICOIDS IN MAN. 68
Effects of vitamin E supplementation on F2-isoprostane and thromboxane biosynthesis in healthy cigarette smokers. 68
Functionalized diarylisoxazoles inhibitors of ciclooxygenase 68
Managing the adverse effects of nonsteroidal anti-inflammatory drugs. 68
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCIBLE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS. 67
INCREASED OXIDATIVE STRESS IN RENOVASCULAR HYPERTENSION. 67
EFFECTS OF ACETAMINOPHEN ON CONSTITUTIVE AND INDUCILE PROSTANOID BIOSYNTHESIS IN HUMAN BLOOD CELLS IN VITRO. 67
ISOPROSTANES: ARE THEY MORE THAN PHYSIOPATHOLOGICAL BIOMARKERS OF LIPID PEROXIDATION? RESPONSE. 67
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES 66
Reduced thromboxane biosynthesis in carriers of Toll-like receptor 4 polymorphisms in vivo 66
Differential association between human prostacyclin receptor polymorphisms and the development of venous thrombosis and intimal hyperplasia: a clinical biomarker study. 65
Pharmacological characterization of the biosynthesis of prostanoids and hydroxyeicosatetraenoic acids in human whole blood and platelets by targeted chiral lipidomics analysis 65
Clinical pharmacology of platelet, monocyte, and vascular cyclooxygenase inhibition by naproxen and low-dose aspirin in healthy subjects. 64
Parmacodynamic interaction of naproxen with low-dose aspirin in healthy subjects 64
Variability among nonsteroidal antiinflammatory drugs in risk of upper gastrointestinal bleeding. 63
Aspirin-triggered lipoxin in patients treated with aspirin and selective vs. non-selective COX-2 inhibitors 63
The antiplatelet agent revacept prevents the increase of systemic thromboxane A2 biosynthesis and neointima hyperplasia 63
null 62
Antiplatelet Agents Affecting GPCR Signaling Implicated in Tumor Metastasis 62
Tumor-Educated Platelet Extracellular Vesicles: Proteomic Profiling and Crosstalk with Colorectal Cancer Cells 61
OXIDANT STRESS AND PLATELET ACTIVATION IN ESSENTIAL HYPERTENSION. 61
Mode of action of aspirin as a chemopreventive agent. 61
Coxibs: pharmacology, toxicity and efficacy in cancer clinical trials. 61
ENHANCED CORTISOL SECRETION DOES NOT CONTROL ASPIRIN-INSENSITIVE THROMBOXANE BIOSYNTHESIS IN PATIENTS WITH ACUTE CORONARY SYNDROMES. 60
Correlazione tra aumentata secrezione di cortisolo e marker di infiammazione nei pazienti con sindromi coronariche acute 59
Multifaceted Functions of Platelets in Cancer: From Tumorigenesis to Liquid Biopsy Tool and Drug Delivery System 59
Isoprostanes and other markers of peroxidation in atherosclerosis. 57
Totale 8.296
Salva come PNG Salva come JPEG
Categoria #
all - tutte 41.916
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 41.916
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021752 110 2 107 8 69 129 29 23 51 124 47 53
2021/2022489 7 11 14 132 16 5 16 43 45 14 56 130
2022/20231.732 124 220 78 223 165 347 100 136 230 21 30 58
2023/2024808 52 31 69 25 63 225 183 23 5 19 9 104
2024/20251.792 123 272 198 43 52 98 66 141 152 98 219 330
2025/2026197 197 0 0 0 0 0 0 0 0 0 0 0
Totale 9.239